Pathway signature and cellular differentiation in clear cell renal cell carcinoma

PLoS ONE

Volumn 5, Issue 5, 2010, Pages

  Tun, Han W ^a   Marlow, Laura A ^a   von Roemeling, Christina A ^a   Cooper, Simon J ^a   Kreinest, Pamela ^a   Wu, Kevin ^a   Luxon, Bruce A ^b   Sinha, Mala ^b   Anastasiadis, Panos Z ^a   Copland, John A ^a  

^a MAYO CLINIC   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOUBLESEX MAB 3 RELATED TRANSCRIPTION FACTOR 2; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ACTIVATING PROTEIN 2BETA; TRANSCRIPTION FACTOR CP2 LIKE 1; TRANSCRIPTION FACTOR GATA 3; UNCLASSIFIED DRUG; TUMOR MARKER;

ADIPOGENESIS; ARTICLE; BONE DEVELOPMENT; CANCER STAGING; CARCINOGENESIS; CELL DIFFERENTIATION; CELL STRUCTURE; CLEAR CELL CARCINOMA; CONTROLLED STUDY; DNA SEQUENCE; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE CLUSTER; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENETIC MARKER; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; KIDNEY CARCINOMA; KIDNEY DEVELOPMENT; KIDNEY EPITHELIUM; NUCLEOTIDE SEQUENCE; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; BIOLOGICAL MODEL; CELL TRANSDIFFERENTIATION; EPITHELIUM; GENETICS; KIDNEY; KIDNEY TUMOR; MESODERM; METABOLISM; PATHOLOGY; REPRODUCIBILITY;

ADIPOGENESIS; CARCINOMA, RENAL CELL; CELL DIFFERENTIATION; CELL TRANSDIFFERENTIATION; EPITHELIUM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KIDNEY; KIDNEY NEOPLASMS; MESODERM; MODELS, BIOLOGICAL; OSTEOGENESIS; REPRODUCIBILITY OF RESULTS; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 77955158430     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0010696     Document Type: Article

References (69)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2009) Cancer Statistics, 2009. CA Cancer J Clin 59: 225-249.
2. Cheville JC, Lohse CM, Zincke H, Weaver AL, Blute ML (2003) Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol 27: 612-624.
3. Eble J, Sauter G, Epstein J, eds (2004) Tumors of the kidney. Lyon, France: IARC Press;2004.
4. Rezende RB, Drachenberg CB, Kumar D, Blanchaert R, Ord RA, et al. (1999) Differential diagnosis between monomorphic clear cell adenocarcinoma of salivary glands and renal (clear) cell carcinoma. Am J Surg Pathol 23: 1532-1538.
5. Yao M, Tabuchi H, Nagashima Y, Baba M, Nakaigawa N, et al. (2005) Gene expression analysis of renal carcinoma: adipose differentiation-related protein as a potential diagnostic and prognostic biomarker for clear-cell renal carcinoma. J Pathol 205: 377-387.
6. Takahashi M, Teh BT, Kanayama HO (2006) Elucidation of the molecular signatures of renal cell carcinoma by gene expression profiling. J Med Invest 53: 9-19.
7. Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, et al. (2003) PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 34: 267-273.
8. Tian L, Greenberg SA, Kong SW, Altschuler J, Kohane IS, et al. (2005) Discovering statistically significant pathways in expression profiling studies. Proc Natl Acad Sci U S A 102: 13544-13549.
9. Cooper SJ, Zou H, LeGrand SN, Marlow LA, von Roemeling CA, et al. (2010) Loss of type III transforming growth factor-[beta] receptor expression is due to methylation silencing of the transcription factor GATA3 in renal cell carcinoma. Oncogene.
10. Yamaguchi Y, Yonemura S, Takada S (2006) Grainyhead-related transcription factor is required for duct maturation in the salivary gland and the kidney of the mouse. Development 133: 4737-4748.
11. Gumz ML, Zou H, Kreinest PA, Childs AC, Belmonte LS, et al. (2007) Secreted frizzled-related protein 1 loss contributes to tumor phenotype of clear cell renal cell carcinoma. Clin Cancer Res 13: 4740-4749.
12. Pico AR KT, van Iersel MP, Hanspers K, Conklin BR, Evelo C (2008) WikiPathways:Pathway Editing for the people. PLoS Biol 6(7): doi:101371/journalpbio0060184.
13. Vankoningsloo S, De Pauw A, Houbion A, Tejerina S, Demazy C, et al. (2006) CREB activation induced by mitochondrial dysfunction triggers triglyceride accumulation in 3T3-L1 preadipocytes. J Cell Sci 119: 1266-1282.
14. Rosen ED, Walkey CJ, Puigserver P, Spiegelman BM (2000) Transcriptional regulation of adipogenesis. Genes Dev 14: 1293-1307.
15. Desvergne B, Michalik L, Wahli W (2006) Transcriptional regulation of metabolism. Physiol Rev 86: 465-514.
16. Tang QQ, Otto TC, Lane MD (2003) CCAAT/enhancer-binding protein beta is required for mitotic clonal expansion during adipogenesis. Proc Natl Acad Sci U S A 100: 850-855.
17. Koster A, Chao YB, Mosior M, Ford A, Gonzalez-DeWhitt PA, et al. (2005) Transgenic angiopoietin-like (angptl)4 overexpression and targeted disruption of angptl4 and angptl3: regulation of triglyceride metabolism. Endocrinology 146: 4943-4950.
18. Yoon JC, Chickering TW, Rosen ED, Dussault B, Qin Y, et al. (2000) Peroxisome proliferator-activated receptor gamma target gene encoding a novel angiopoietin-related protein associated with adipose differentiation. Mol Cell Biol 20: 5343-5349.
19. Ntambi JM, Miyazaki M (2004) Regulation of stearoyl-CoA desaturases and role in metabolism. Prog Lipid Res 43: 91-104.
20. Tong Q, Dalgin G, Xu H, Ting CN, Leiden JM, et al. (2000) Function of GATA transcription factors in preadipocyte-adipocyte transition. Science 290: 134-138.
21. Tong Q, Tsai J, Tan G, Dalgin G, Hotamisligil GS (2005) Interaction between GATA and the C/EBP family of transcription factors is critical in GATAmediated suppression of adipocyte differentiation. Mol Cell Biol 25: 706-715.
22. Le Lay S, C MB, Hajduch E, Dugail I (2009) Filling up adipocytes with lipids. Lessons from caveolin-1 deficiency. Biochim Biophys Acta 1791: 514-518.
23. Le Lay S, Kurzchalia TV (2005) Getting rid of caveolins: phenotypes of caveolin-deficient animals. Biochim Biophys Acta 1746: 322-333.
24. Jechlinger M, Grunert S, Tamir IH, Janda E, Ludemann S, et al. (2003) Expression profiling of epithelial plasticity in tumor progression. Oncogene 22: 7155-7169.
25. Beham A, Ratschek M, Zatloukal K, Schmid C, Denk H (1992) Distribution of cytokeratins, vimentin and desmoplakins in normal renal tissue, renal cell carcinomas and oncocytoma as revealed by immunofluorescence microscopy. Virchows Arch A Pathol Anat Histopathol 421: 209-215.
26. Donhuijsen K, Schulz S (1989) Prognostic significance of vimentin positivity in formalin-fixed renal cell carcinomas. Pathol Res Pract 184: 287-291.
27. He Z, Liu S, Guo M, Mao J, Hughson MD (2004) Expression of fibronectin and HIF-1alpha in renal cell carcinomas: relationship to von Hippel-Lindau gene inactivation. Cancer Genet Cytogenet 152: 89-94.
28. Lohi J, Tani T, Laitinen L, Kangas L, Lehto VP, et al. (1995) Tenascin and fibronectin isoforms in human renal cell carcinomas, renal cell carcinoma cell lines and xenografts in nude mice. Int J Cancer 63: 442-449.
29. Perroud B, Lee J, Valkova N, Dhirapong A, Lin PY, et al. (2006) Pathway analysis of kidney cancer using proteomics and metabolic profiling. Mol Cancer 5: 64.
30. Gmeiner WH, Hellmann GM, Shen P (2008) Tissue-dependent and - independent gene expression changes in metastatic colon cancer. Oncol Rep 19: 245-251.
31. Hervouet E, Cizkova A, Demont J, Vojtiskova A, Pecina P, et al. (2008) HIF and reactive oxygen species regulate oxidative phosphorylation in cancer. Carcinogenesis 29: 1528-1537.
32. Semenza GL (2007) HIF-1 mediates the Warburg effect in clear cell renal carcinoma. J Bioenerg Biomembr 39: 231-234.
33. Schuetz AN, Yin-Goen Q, Amin MB, Moreno CS, Cohen C, et al. (2005) Molecular classification of renal tumors by gene expression profiling. J Mol Diagn 7: 206-218.
34. Miyake K (2007) Innate immune sensing of pathogens and danger signals by cell surface Toll-like receptors. Semin Immunol 19: 3-10.
35. Johnson GB, Brunn GJ, Tang AH, Platt JL (2003) Evolutionary clues to the functions of the Toll-like family as surveillance receptors. Trends Immunol 24: 19-24.
36. Balkwill F (2004) The significance of cancer cell expression of the chemokine receptor CXCR4. Semin Cancer Biol 14: 171-179.
37. Schaefer L, Babelova A, Kiss E, Hausser HJ, Baliova M, et al. (2005) The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages. J Clin Invest 115: 2223-2233.
38. Scheibner KA, Lutz MA, Boodoo S, Fenton MJ, Powell JD, et al. (2006) Hyaluronan fragments act as an endogenous danger signal by engaging TLR2. J Immunol 177: 1272-1281.
39. Park JS, Svetkauskaite D, He Q, Kim JY, Strassheim D, et al. (2004) Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem 279: 7370-7377.
40. Petit I, Jin D, Rafii S (2007) The SDF-1-CXCR4 signaling pathway: a molecular hub modulating neo-angiogenesis. Trends Immunol 28: 299-307.
41. Pan J, Mestas J, Burdick MD, Phillips RJ, Thomas GV, et al. (2006) Stromal derived factor-1 (SDF-1/CXCL12) and CXCR4 in renal cell carcinoma metastasis. Mol Cancer 5: 56.
42. Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, et al. (2002) Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res 62: 1832-1837.
43. Schioppa T, Uranchimeg B, Saccani A, Biswas SK, Doni A, et al. (2003) Regulation of the chemokine receptor CXCR4 by hypoxia. J Exp Med 198: 1391-1402.
44. Yoon Y, Liang Z, Zhang X, Choe M, Zhu A, et al. (2007) CXC chemokine receptor-4 antagonist blocks both growth of primary tumor and metastasis of head and neck cancer in xenograft mouse models. Cancer Res 67: 7518-7524.
45. Tamamura H, Hori A, Kanzaki N, Hiramatsu K, Mizumoto M, et al. (2003) T140 analogs as CXCR4 antagonists identified as anti-metastatic agents in the treatment of breast cancer. FEBS Lett 550: 79-83.
46. Morikawa T, Sugiyama A, Kume H, Ota S, Kashima T, et al. (2007) Identification of Toll-like receptor 3 as a potential therapeutic target in clear cell renal cell carcinoma. Clin Cancer Res 13: 5703-5709.
47. Krambeck AE, Dong H, Thompson RH, Kuntz SM, Lohse CM, et al. (2007) Survivin and b7-h1 are collaborative predictors of survival and represent potential therapeutic targets for patients with renal cell carcinoma. Clin Cancer Res 13: 1749-1756.
48. Motzer RJ, Bacik J, Mariani T, Russo P, Mazumdar M, et al. (2002) Treatment outcome and survival associated with metastatic renal cell carcinoma of nonclear-cell histology. J Clin Oncol 20: 2376-2381.
49. Upton MP, Parker RA, Youmans A, McDermott DF, Atkins MB (2005) Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy. J Immunother 28: 488-495.
50. Zhao H, Zongming M, Tibshirani R, Higgins JP, Ljungberg B, et al. (2009) Alteration of gene expression signatures of cortical differentiation and wound response in lethal clear cell renal cell carcinomas. PLoS One 4: e6039.
51. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, et al. (2008) The epithelialmesenchymal transition generates cells with properties of stem cells. Cell 133: 704-715.
52. Amato RJ (2000) Chemotherapy for renal cell carcinoma. Semin Oncol 27: 177-186.
53. Rini BI, Atkins MB (2009) Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol 10: 992-1000.
54. Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, et al. (2009) Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 138: 645-659.
55. Airik R, Karner M, Karis A, Karner J (2005) Gene expression analysis of Gata3-/- mice by using cDNA microarray technology. Life Sci 76: 2559-2568.
56. Labastie MC, Catala M, Gregoire JM, Peault B (1995) The GATA-3 gene is expressed during human kidney embryogenesis. Kidney Int 47: 1597-1603.
57. Grote D, Souabni A, Busslinger M, Bouchard M (2006) Pax 2/8-regulated Gata 3 expression is necessary for morphogenesis and guidance of the nephric duct in the developing kidney. Development 133: 53-61.
58. Ferraris S, Del Monaco AG, Garelli E, Carando A, De Vito B, et al. (2009) HDR syndrome: a novel ''de novo'' mutation in GATA3 gene. Am J Med Genet A 149A: 770-775.
59. Van Esch H, Groenen P, Nesbit MA, Schuffenhauer S, Lichtner P, et al. (2000) GATA3 haplo-insufficiency causes human HDR syndrome. Nature 406: 419-422.
60. Wang L, Wildt KF, Zhu J, Zhang X, Feigenbaum L, et al. (2008) Distinct functions for the transcription factors GATA-3 and ThPOK during intrathymic differentiation of CD4(+) T cells. Nat Immunol 9: 1122-1130.
61. UniProt T (2009) The Universal Protein Resource (UniProt) 2009. Nucleic Acids Res 37: D169-174.
62. Moser M, Pscherer A, Roth C, Becker J, Mucher G, et al. (1997) Enhanced apoptotic cell death of renal epithelial cells in mice lacking transcription factor AP-2beta. Genes Dev 11: 1938-1948.
63. Seo KW (2007) Dmrt2 and Pax3 double-knockout mice show severe defects in embryonic myogenesis. Comp Med 57: 460-468.
64. Ottolenghi C, Veitia R, Barbieri M, Fellous M, McElreavey K (2000) The human doublesex-related gene, DMRT2, is homologous to a gene involved in somitogenesis and encodes a potential bicistronic transcript. Genomics 64: 179-186.
65. Ounap K, Uibo O, Zordania R, Kiho L, Ilus T, et al. (2004) Three patients with 9p deletions including DMRT1 and DMRT2: a girl with XY complement, bilateral ovotestes, and extreme growth retardation, and two XX females with normal pubertal development. Am J Med Genet A 130A: 415-423.
66. Lipschutz JH (1998) Molecular development of the kidney: a review of the results of gene disruption studies. Am J Kidney Dis 31: 383-397.
67. Polyak K, Weinberg RA (2009) Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 9: 265-273.
68. Tun HW, Personett D, Baskerville KA, Menke DM, Jaeckle KA, et al. (2008) Pathway analysis of primary central nervous system lymphoma. Blood 111: 3200-3210.
69. Eisen MB, Spellman PT, Brown PO, Botstein D (1998) Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 95: 14863-14868.